Global /United States /Healthcare /Drug Manufacturers - General /JNJ
chevron_leftBack

Johnson & Johnson

JNJ
NYSE: JNJ Delayed
155.24USD -1.6%
As of 24 April 2025, Johnson & Johnson has a market cap of $374.1B USD, ranking #23 globally and #20 in the United States. It ranks #3 in the Healthcare sector, and #2 in the Drug Manufacturers - General industry.
Global Rank
23
Country Rank
20
Sector Rank
3
Industry Rank
2
Key Stats
Market Cap
$374.1BUSD
Enterprise Value
$387.75BUSD
Revenue (TTM)
$89.33BUSD
EBITDA (TTM)
$30.07BUSD
Net Income (TTM)
$21.81BUSD
EBITDA Margin
34%
Profit Margin
24%
PE Ratio
17.3
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Joaquin Duato open_in_new
Employees
138,100
Founded
1886
IPO
24 Sep 1944
Website
jnj.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-1.6% 0.9% -5.1% 6.9% -5% 4.1%

Markets

Exchange Ticker Price
NYSE
MIC: XNYS
PRIMARY
JNJ
ISIN: US4781601046
Shares Out.:
2.41B1 Shares Float: 2.407B2
TV:
SA:
YF:
JNJ
GF:
NQ:
JNJ
BA:
JNJ
MS:
155.24 USD
London Stock Exchange
MIC: XLON
0R34
ISIN: US4781601046
TV:
SA:
YF:
GF:
BA:
MS:
157.90 USD
Borsa Italiana
MIC: XMIL
1JNJ
ISIN: US4781601046
TV:
SA:
YF:
GF:
BA:
MS:
138.92 EUR
Cboe Canada
MIC: NEOE
JNJ
Johnson & Johnson Canadian Depository Receipt (CAD Hedged)
ISIN: CA47817E1034
TV:
SA:
YF:
GF:
BA:
JNJ
MS:
20.48 CAD
Deutsche Börse Xetra
MIC: XETR
JNJ
ISIN: US4781601046
TV:
SA:
YF:
GF:
BA:
JNJ
MS:
136.54 EUR
Frankfurt Stock Exchange
MIC: XFRA
JNJ
ISIN: US4781601046
TV:
SA:
YF:
GF:
BA:
JNJ
MS:
136.54 EUR
Mexican Bolsa
MIC: XMEX
JNJ
Johnson & Johnson
ISIN: US4781601046
TV:
SA:
YF:
GF:
BA:
JNJ
MS:
3.09K MXN
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; circulatory restoration products for the treatment of calcified coronary artery and peripheral artery diseases; and neurovascular care that treats hemorrhagic and ischemic stroke. This segment offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Similar Companies

Industry: Drug Manufacturers - General (United States)
Name
Market Cap diff.
Eli Lilly and Co.
LLY
$744.65B
99%
AbbVie Inc.
ABBV
$313.02B
-16%
Merck & Co., Inc.
MRK
$198.0B
-47%
Amgen Inc.
AMGN
$149.41B
-60%
Gilead Sciences, Inc.
GILD
$132.62B
-65%
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
Novo Nordisk A/S
NOVO-B
$262.78B
1.73T DKK
-30%
Roche Holding AG
RO
$246.36B
204.44B CHF
-34%
AstraZeneca PLC
AZN
$213.18B
160.68B GBP
-43%
Novartis AG
NOVN
$207.35B
172.07B CHF
-45%
Sanofi
SAN
$129.34B
114.13B EUR
-65%